Diagnosis in General

  • Hirokazu KashiwagiEmail author
  • Yoshiaki Tomiyama


Diagnosis of ITP is carried out by mainly exclusion of thrombocytopenia caused by other etiology and therapeutic responses. Since thrombocytopenia may be associated with a variety of clinical conditions, careful exclusion is necessary. Blood smear examination is especially important to rule out pseudothrombocytopenia and some congenital thrombocytopenia. Bone marrow examination may not be essential to ITP diagnosis, but it should be performed in cases with abnormalities in CBC or blood smear other than thrombocytopenia, atypical clinical course, or refractory to standard treatments. Assessment of reticulated platelets and plasma thrombopoietin concentration may be helpful to distinguish ITP from hypoplastic thrombocytopenia.


Aplastic Anemia Disseminate Intravascular Coagulation Bone Marrow Examination Common Variable Immunodeficiency Antiplatelet Antibody 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.



This work was supported by Grant-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology and the Ministry of Health, Labour and Welfare in Japan.


  1. 1.
    Kashiwagi H, Tomiyama Y. Pathophysiology and management of primary immune thrombocytopenia. Int J Hematol. 2013;98(1):24–33.CrossRefPubMedGoogle Scholar
  2. 2.
    Provan D, Stasi R, Newland AC, Blanchette VS, Bolton-Maggs P, Bussel JB, et al. International consensus report on the investigation and management of primary immune thrombocytopenia. Blood. 2010;115(2):168–86.CrossRefPubMedGoogle Scholar
  3. 3.
    Berkman N, Michaeli Y, Or R, Eldor A. EDTA-dependent pseudothrombocytopenia: a clinical study of 18 patients and a review of the literature. Am J Hematol. 1991;36(3):195–201.CrossRefPubMedGoogle Scholar
  4. 4.
    Kunishima S, Saito H. Advances in the understanding of MYH9 disorders. Curr Opin Hematol. 2010;17(5):405–10.CrossRefPubMedGoogle Scholar
  5. 5.
    Bolton-Maggs PH, Chalmers EA, Collins PW, Harrison P, Kitchen S, Liesner RJ, et al. A review of inherited platelet disorders with guidelines for their management on behalf of the UKHCDO. Br J Haematol. 2006;135(5):603–33.CrossRefPubMedGoogle Scholar
  6. 6.
    Kim KJ, Baek IW, Yoon CH, Kim WU, Cho CS. Thrombotic risk in patients with immune thrombocytopenia and its association with antiphospholipid antibodies. Br J Haematol. 2013;161(5):706–14.CrossRefPubMedGoogle Scholar
  7. 7.
    Stasi R, Stipa E, Masi M, Oliva F, Sciarra A, Perrotti A, et al. Prevalence and clinical significance of elevated antiphospholipid antibodies in patients with idiopathic thrombocytopenic purpura. Blood. 1994;84(12):4203–8.PubMedGoogle Scholar
  8. 8.
    Nichols WL, Hultin MB, James AH, Manco-Johnson MJ, Montgomery RR, Ortel TL, et al. von Willebrand disease (VWD): evidence-based diagnosis and management guidelines, the National Heart, Lung, and Blood Institute (NHLBI) Expert Panel report (USA). Haemophilia. 2008;14(2):171–232.CrossRefPubMedGoogle Scholar
  9. 9.
    Liebman HA, Stasi R. Secondary immune thrombocytopenic purpura. Curr Opin Hematol. 2007;14(5):557–73.CrossRefPubMedGoogle Scholar
  10. 10.
    Stasi R, Willis F, Shannon MS, Gordon-Smith EC. Infectious causes of chronic immune thrombocytopenia. Hematol Oncol Clin North Am. 2009;23(6):1275–97.CrossRefPubMedGoogle Scholar
  11. 11.
    Kuwana M. Helicobacter pylori-associated immune thrombocytopenia: clinical features and pathogenic mechanisms. World J Gastroenterol. 2014;20(3):714–23.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Karpatkin S, Nardi MA, Hymes KB. Sequestration of anti-platelet GPIIIa antibody in rheumatoid factor immune complexes of human immunodeficiency virus 1 thrombocytopenic patients. Proc Natl Acad Sci U S A. 1995;92(6):2263–7.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Lacey JV, Penner JA. Management of idiopathic thrombocytopenic purpura in the adult. Semin Thromb Hemost. 1977;3(3):160–74.PubMedGoogle Scholar
  14. 14.
    Jubelirer SJ, Harpold R. The role of the bone marrow examination in the diagnosis of immune thrombocytopenic purpura: case series and literature review. Clin Appl Thromb Hemost. 2002;8(1):73–6.CrossRefPubMedGoogle Scholar
  15. 15.
    Mahabir VK, Ross C, Popovic S, Sur ML, Bourgeois J, Lim W, et al. A blinded study of bone marrow examinations in patients with primary immune thrombocytopenia. Eur J Haematol. 2013;90(2):121–6.CrossRefPubMedGoogle Scholar
  16. 16.
    Neunert C, Lim W, Crowther M, Cohen A, Solberg L, Crowther MA, et al. The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia. Blood. 2011;117(16):4190–207.CrossRefPubMedGoogle Scholar
  17. 17.
    Kantarjian H, Fenaux P, Sekeres MA, Becker PS, Boruchov A, Bowen D, et al. Safety and efficacy of romiplostim in patients with lower-risk myelodysplastic syndrome and thrombocytopenia. J Clin Oncol. 2010;28(3):437–44.CrossRefPubMedGoogle Scholar
  18. 18.
    Oshima Y, Yuji K, Tanimoto T, Hinomura Y, Tojo A. Association between acute myelogenous leukemia and thrombopoietin receptor agonists in patients with immune thrombocytopenia. Intern Med. 2013;52(19):2193–201.CrossRefPubMedGoogle Scholar
  19. 19.
    Prica A, Sholzberg M, Buckstein R. Safety and efficacy of thrombopoietin-receptor agonists in myelodysplastic syndromes: a systematic review and meta-analysis of randomized controlled trials. Br J Haematol. 2014;167(5):626–38.CrossRefPubMedGoogle Scholar
  20. 20.
    Najean Y, Lecompte T. Chronic pure thrombocytopenia in elderly patients. An aspect of the myelodysplastic syndrome. Cancer. 1989;64(12):2506–10.CrossRefPubMedGoogle Scholar
  21. 21.
    Gupta R, Soupir CP, Johari V, Hasserjian RP. Myelodysplastic syndrome with isolated deletion of chromosome 20q: an indolent disease with minimal morphological dysplasia and frequent thrombocytopenic presentation. Br J Haematol. 2007;139(2):265–8.CrossRefPubMedGoogle Scholar
  22. 22.
    Mittal S, Blaylock MG, Culligan DJ, Barker RN, Vickers MA. A high rate of CLL phenotype lymphocytes in autoimmune hemolytic anemia and immune thrombocytopenic purpura. Haematologica. 2008;93(1):151–2.CrossRefPubMedGoogle Scholar
  23. 23.
    Heitink-Polle KM, Nijsten J, Boonacker CW, de Haas M, Bruin MC. Clinical and laboratory predictors of chronic immune thrombocytopenia in children: a systematic review and meta-analysis. Blood. 2014;124(22):3295–307.CrossRefPubMedGoogle Scholar
  24. 24.
    Artim-Esen B, Diz-Kucukkaya R, Inanc M. The significance and management of thrombocytopenia in antiphospholipid syndrome. Curr Rheumatol Rep. 2015;17(3):14.CrossRefPubMedGoogle Scholar
  25. 25.
    Meyer O. Symptoms and diagnosis. In: Salama A, editor. Current & emerging treatments for immune thrombocytopenia. London: Future Medicine; 2013. p. 19–29.Google Scholar
  26. 26.
    Kelton JG, Murphy WG, Lucarelli A, Garvey-Williams J, Santos A, Meyer R, et al. A prospective comparison of four techniques for measuring platelet-associated IgG. Br J Haematol. 1989;71(1):97–105.CrossRefPubMedGoogle Scholar
  27. 27.
    Mueller-Eckhardt C, Kayser W, Mersch-Baumert K, Mueller-Eckhardt G, Breidenbach M, Kugel HG, et al. The clinical significance of platelet-associated IgG: a study on 298 patients with various disorders. Br J Haematol. 1980;46(1):123–31.CrossRefPubMedGoogle Scholar
  28. 28.
    Kiyomizu K, Kashiwagi H, Nakazawa T, Tadokoro S, Honda S, Kanakura Y, et al. Recognition of highly restricted regions in the β-propeller domain of αIIb by platelet-associated anti-αIIbβ3 autoantibodies in primary immune thrombocytopenia. Blood. 2012;120(7):1499–509.CrossRefPubMedGoogle Scholar
  29. 29.
    Kuwana M, Kurata Y, Fujimura K, Fujisawa K, Wada H, Nagasawa T, et al. Preliminary laboratory based diagnostic criteria for immune thrombocytopenic purpura: evaluation by multi-center prospective study. J Thromb Haemost. 2006;4(9):1936–43.CrossRefPubMedGoogle Scholar
  30. 30.
    Warner MN, Moore JC, Warkentin TE, Santos AV, Kelton JG. A prospective study of protein-specific assays used to investigate idiopathic thrombocytopenic purpura. Br J Haematol. 1999;104(3):442–7.CrossRefPubMedGoogle Scholar
  31. 31.
    Brighton TA, Evans S, Castaldi PA, Chesterman CN, Chong BH. Prospective evaluation of the clinical usefulness of an antigen-specific assay (MAIPA) in idiopathic thrombocytopenic purpura and other immune thrombocytopenias. Blood. 1996;88(1):194–201.PubMedGoogle Scholar
  32. 32.
    McMillan R, Wang L, Tani P. Prospective evaluation of the immunobead assay for the diagnosis of adult chronic immune thrombocytopenic purpura (ITP). J Thromb Haemost. 2003;1(3):485–91.CrossRefPubMedGoogle Scholar
  33. 33.
    Saito C, Ishiyama K, Yamazaki H, Zaimoku Y, Nakao S. Hypomegakaryocytic thrombocytopenia (HMT): an immune-mediated bone marrow failure characterized by an increased number of PNH-phenotype cells and high plasma thrombopoietin levels. Br J Haematol. 2016;175(2):246–51.CrossRefPubMedGoogle Scholar
  34. 34.
    Kaushansky K. The molecular mechanisms that control thrombopoiesis. J Clin Invest. 2005;115(12):3339–47.CrossRefPubMedPubMedCentralGoogle Scholar
  35. 35.
    Grozovsky R, Begonja AJ, Liu K, Visner G, Hartwig JH, Falet H, et al. The Ashwell-Morell receptor regulates hepatic thrombopoietin production via JAK2-STAT3 signaling. Nat Med. 2015;21(1):47–54.CrossRefPubMedGoogle Scholar
  36. 36.
    Kurata Y, Hayashi S, Kiyoi T, Kosugi S, Kashiwagi H, Honda S, et al. Diagnostic value of tests for reticulated platelets, plasma glycocalicin, and thrombopoietin levels for discriminating between hyperdestructive and hypoplastic thrombocytopenia. Am J Clin Pathol. 2001;115(5):656–64.CrossRefPubMedGoogle Scholar
  37. 37.
    Kienast J, Schmitz G. Flow cytometric analysis of thiazole orange uptake by platelets: a diagnostic aid in the evaluation of thrombocytopenic disorders. Blood. 1990;75(1):116–21.PubMedGoogle Scholar
  38. 38.
    Richards EM, Baglin TP. Quantitation of reticulated platelets: methodology and clinical application. Br J Haematol. 1995;91(2):445–51.CrossRefPubMedGoogle Scholar
  39. 39.
    Sakuragi M, Hayashi S, Maruyama M, Kabutomori O, Kiyokawa T, Nagamine K, et al. Clinical significance of IPF% or RP% measurement in distinguishing primary immune thrombocytopenia from aplastic thrombocytopenic disorders. Int J Hematol. 2015;101(4):369–75.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Nature Singapore Pte Ltd. 2017

Authors and Affiliations

  1. 1.Department of Hematology and Oncology, Graduate School of MedicineOsaka UniversitySuitaJapan
  2. 2.Department of Blood TransfusionOsaka University HospitalSuitaJapan

Personalised recommendations